Видео с ютуба Tropion-Lung05

TROPION-Lung01 & TROPION-Lung05: datopotamab deruxtecan for NSCLC

FDA Approval of Datopotamab deruxtecan (Dato-DXd) in EGFR Mutated Lung Cancer - Dr. Jacob Sands

Current and Future Role of TROP2-Directed Antibody-Drug Conjugates in Non-Small Cell Lung Cancer

Datopotamab Deruxtecan in NSCLC: A Closer Look at TROP2-Targeted Therapy

Defining the Future Role of TROP2-Directed Antibody-Drug Conjugates in Non-Small Cell Lung Cancer

Достижения в лечении рака легких: влияние DATO-DXD на результаты лечения пациентов.

The evolving role of datopotamab deruxtecan in lung cancer

Defining the Future Role of TROP2-Directed Antibody-Drug Conjugates in Non-Small Cell Lung Cancer

Ongoing studies for datopotamab deruxtecan in NSCLC

Addressing controversies in biomarkers for ADCs in lung cancer

Evaluating Dato-DXd for EGFR-Mutated Advanced NSCLC: Data from a Pooled Analysis

Эффективность, безопасность и тактика лечения с использованием препарата Dato-DXd при раке легких...

Highlights on datopotamab deruxtecan in advanced NSCLC: The TROPION-Lung01 study

Клинические данные: Dato-DXd при немелкоклеточном раке легких с мутацией EGFR.

TROPION-Lung01 Comparing the datopotamab deruxtecan (Dato-DXd) to Docetaxel in Patients with mNSCLC

Non-TKI-based treatment options for EGFR-mutant lung cancer

Stage 3 Unresectable NSCLC: The PACIFIC Trial

Antibody drug conjugates in lung cancer

‘Mixed Bag’: Only a Fraction of Recent Drug Approvals in NSCLC Space ‘Considered Practice Changing’

Dr. Garon on the Role of Trastuzumab Deruxtecan in Lung Cancer